Genetic factors associated with response to as-needed aflibercept therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
Open Access
- 28 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 10 (1), 1-7
- https://doi.org/10.1038/s41598-020-64301-z
Abstract
In the present study, we investigated the association between susceptible genetic variants to age-related macular degeneration (AMD) and response to as-needed intravitreal aflibercept injection (IAI) therapy for exudative AMD including both typical neovascular AMD and polypoidal choroidal vasculopathy (PCV) over 12-months. A total of 234 patients with exudative AMD were initially treated with 3 monthly IAI and thereafter as-needed IAI over 12 months. Seven variants of 6 genes including ARMS2 A69S (rs10490924), CFH (I62V:rs800292 and rs1329428), C2-CFB-SKIV2L(rs429608), C3 (rs2241394), CETP (rs3764261) and ADAMTS-9 (rs6795735) were genotyped for all participants using TaqMan technology. After adjusting for age, gender, baseline BCVA and AMD subtype, A (protective) allele of C2-CFB-SKIV2L rs429608 was associated with visual improvement at 12-month (P = 0.003). Retreatment was associated with T(risk) allele of ARMS2 A69S (P = 2.0 × 10−4; hazard ratio: 2.18:95%CI: 1.47-3.24) and C(risk) allele of CFH rs1329428 (P = 2.0 × 10−3; hazard ratio: 1.74:95%CI: 1.16–2.59) after adjusting for the baseline confounders. The need for additional injections was also associated with T allele of ARMS2 A69S (P = 1.0 × 10−5) and C allele of CFH rs1329428 (P = 3.0 × 10−3) after adjusting for the baseline confounders. The variants of ARMS2 and CFH are informative for both physicians and patients to predict recurrence and to quantify the need for additional injections.Funding Information
- MEXT | Japan Society for the Promotion of Science (19K18841)
This publication has 24 references indexed in Scilit:
- A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degenerationScientific Reports, 2017
- A missense variant in FGD6 confers increased risk of polypoidal choroidal vasculopathyNature Genetics, 2016
- Prevalence and Genetic Characteristics of Geographic Atrophy among Elderly Japanese with Age-Related Macular DegenerationPLOS ONE, 2016
- New loci and coding variants confer risk for age-related macular degeneration in East AsiansNature Communications, 2015
- Seven new loci associated with age-related macular degenerationNature Genetics, 2013
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2011
- The Prevalence of Age-Related Macular Degeneration in Asians: A Systematic Review and Meta-AnalysisOphthalmology, 2010
- A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO StudyAmerican Journal of Ophthalmology, 2009
- Association of LOC387715 A69S With Vitreous Hemorrhage in Polypoidal Choroidal VasculopathyAmerican Journal of Ophthalmology, 2008